DRG Epidemiology's coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
The number of diagnosed lifetime prevalent cases of schizophrenia in the European countries under study will increase by 16% from 948 thousand to 1 million in 20 years. Of the countries…
The number of diagnosed lifetime prevalent cases of schizophrenia in the Asia-Pacific countries under study will increase by 29% from 3 million to 4 million in 10 years. Of the countries…
The number of diagnosed lifetime prevalent cases of schizophrenia in the countries under study will increase by 19% from 3.2 million to 3.8 million in 10 years. Of the countries considered in…
The total number of diagnosed lifetime prevalent cases of schizophrenia in the countries under study will increase by 40% over from 1 million to 1.4 million in 10 years. Of the countries…
Abstract here
Metastatic squamous non-small-cell lung cancer (NSCLC) is an aggressive form of lung cancer with poor survival outcomes. First-line treatment is limited to chemotherapy or immune checkpoint…
Abstract here
DRG Epidemiology’s coverage Crohn’s disease comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of Crohn’s…
The treatment landscape for COVID-19 is rapidly evolving, as such, intense research is focused on approaches designed to reduce viral load and/or improve outcomes in hospitalized patients infected…
Clarivate Epidemiology's coverage of myasthenia gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and…
DRG Epidemiology's coverage of T2D comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of T2D for each…
DRG Epidemiology's coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key myasthenia gravis patient populations covering 171 countries and…
DRG Epidemiology's coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total symptomatic prevalence of PsO…